Ivana Marešová

A lower dosage of imatinib is sufficient to maintain undetectable disease in patients with chronic myeloid leukemia with long-term low-grade toxicity of the treatment

Tomáš Adam, David Friedecký, M. Jarošová, 2016, Leukemia & lymphoma.